A new strategy for treatment of HCC by regulating hepatic stellate cell

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10165
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Department of Clinical Research, National Hospital Organization Kure Medical Center
• Principal Investigator: Tashiro Hirotaka 独立行政法人国立病院機構(呉医療センター臨床研究部), その他部局等, その他 (90359894)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 肝細胞癌 / 肝星細胞 / 癌間質 / アンチトロンビン

Outline of Final Research Achievements

Antithrombin (AT) is not only a major regulator of hemostasis, but also has anti-inflammatory properties. We aimed to investigate whether AT is associated with development of HCC. Liver tumors were developed in ATIII-insufficient (AT＋/－) mice and wild-type (AT＋/＋) mice treated with DEN and CCl4. Tumor size and the number of DEN and CCl4-induced liver tumors were significantly enhanced in AT-insufficient mice compared with wild-type mice. The serum transaminases, cell death and expression of cleaved caspase-3 in livers were exaggerated in AT-insufficient mice compared with wild-type mice. The level of 8-OHdG, a marker of oxidative DNA damage, in liver was significantly increased in AT-insufficient mice compared with wild-type mice. AT insufficiency led to the increased susceptibility to liver-tumorigenesis through amplifying inflammation.

Free Research Field

消化器外科